Ding Yangyang, Sun Cheng, Li Jingrong, Hu Linhui, Li Manman, Liu Jun, Pu Lianfang, Xiong Shudao
Department of Hematology/Hematological Lab, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Department of Pharmacology, The Second Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
Pathol Oncol Res. 2019 Jan;25(1):311-318. doi: 10.1007/s12253-017-0351-y. Epub 2017 Nov 6.
Long non-coding RNAs (lncRNAs) have been demonstrated that they not only play important roles in tumorgenicity but also associate with cancer prognosis. Recently, highly up-regulated in liver cancer (HULC) is abnormally expressed in liver cancer and other cancers, and participated in cancers progression; however, it is unclear whether its expression is associated with prognosis. Here, we performed a meta-analysis and systematic review to evaluate the prognostic value and metastasis of HULC in various cancer patients. The meta-analysis was performed using a systematic search of PubMed, Web of Science, ScienceDirect and Wiley Online Library database to eligible studies. The pooled hazard ratios (HRs) with a 95% confidence interval (95% CI) were calculated to assess its prognosis and metastasis in human cancer. A total of 1134 patients from 11 studies were included. The results indicated that overexpression of HULC was associated with poor overall survival (OS) (HR = 1.89, 95% CI: 1.32-2.47). Furthermore, subgroup analysis showed that cancer type (digestive system cancer or non-digestive system cancers) and sample size (more or less than 100) significantly associated between HULC and OS. In addition, overexpression of HULC expression was significantly associated with metastasis in cancers (HR = 2.67, 95% CI: 0.94-4.39). The meta-analysis indicated that lncRNA HULC could serve as a new molecular marker for cancer prognosis and metastasis.
长链非编码RNA（lncRNAs）已被证明不仅在肿瘤发生中起重要作用，还与癌症预后相关。最近，肝癌高表达（HULC）在肝癌和其他癌症中异常表达，并参与癌症进展；然而，其表达是否与预后相关尚不清楚。在此，我们进行了一项荟萃分析和系统评价，以评估HULC在各种癌症患者中的预后价值和转移情况。荟萃分析通过对PubMed、科学网、ScienceDirect和Wiley Online Library数据库进行系统检索，纳入符合条件的研究。计算合并风险比（HRs）及95%置信区间（95%CI），以评估其在人类癌症中的预后和转移情况。共纳入来自11项研究的1134例患者。结果表明，HULC过表达与总生存期（OS）较差相关（HR = 1.89，95%CI：1.32 - 2.47）。此外，亚组分析显示，癌症类型（消化系统癌症或非消化系统癌症）和样本量（大于或小于100）与HULC和OS之间存在显著相关性。此外，HULC表达过与癌症转移显著相关（HR = 2.67，95%CI：0.94 - 4.39）。荟萃分析表明，lncRNA HULC可作为癌症预后和转移的新分子标志物。
